Quotient Sciences advances AI-designed drug product into Phase I clinical study

Company launches clinical study of AI-designed oral formulation following MHRA approval, marking a major milestone in AI-driven drug development.

Dyno unveils next-gen AI-designed gene delivery capsids targeting brain & muscle

This positions its platform as a rapidly evolving engine for next-generation genetic medicine

CII elects R Mukundan as President for 2026-27, Suchitra K Ella named President-Designate

Shashwat Goenka takes over as Vice President of industry body

Thermo Fisher opens flagship US Bioprocess Design Center in Massachusetts

The 4,000-square-foot facility is designed as a hands-on hub where customers can work directly with scientists and engineers

AWS unveils Amazon Bio Discovery to accelerate drug design with AI

Revvity launches Signals BioDesign to transform molecular cloning

The solution integrates key molecular cloning methods—including Golden Gate, Gibson assembly, and restriction/ligation—alongside primer design, Sanger sequencing analysis, and protein translation in a single application

$7 million grant to UW Institute for protein design to fuel next-gen enzyme breakthroughs

The initiative will be led by David Baker, 2024 Nobel Prize winner in Chemistry, IPD director, professor of biochemistry, and HHMI Investigator at the University of Washington

Mosaic Clinical Technologies’ AI breakthrough earns FDA “Breakthrough Device” designation

Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings

Insilico Medicine’s AI-designed Parkinson’s drug cleared for human trials by FDA

The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies

iRegene’s Parkinson’s therapy gains FDA designation

The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases